Caplacizumab-YHDP Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Caplacizumab-YHDP Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
15
Registered trials
28
Result records
1
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Caplacizumab-YHDP can convert its Nanobody profile and vWF biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Caplacizumab-YHDP (query alias: caplacizumab) |
|---|---|
| Modality / target | Nanobody; vWF; vWF inhibitors |
| Highest global status | Approved |
| Originator | Ablynx NV |
| Active developers | Sanofi KK, Sanofi-Aventis Australia Pty Ltd., Ablynx NV |
The MCP disease footprint includes Purpura, Thrombotic Thrombocytopenic, Thrombotic Thrombocytopenic Purpura, Acquired. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| ChiCTR2500095632 | Phase 1 | Not yet recruiting | 50 | PLT count |
| ChiCTR2600127065 | Not Applicable | Not yet recruiting | 366 | H. pylori infection rate |
| NCT05876221 | Not Applicable | Completed | 223 | Reliable description and prediction of platelet responses to caplacizumab |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
UTILIZATION AND EFFICACY OF THERAPEUTIC PLASMA EXCHANGE IN THROMBOTIC MICROANGIOPATHIES: A REAL-WORLD ANALYSIS FROM A NATIONWIDE REGISTRY
Not Applicable; n=156; evaluation: Positive. Reported fields: Recurrence rate = 30.7 %
An Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura
Phase 3; n=51; evaluation: not stated. Reported fields: Percentage of Participants Who Achieved Remission Without Requirement of Therapeutic Plasma Exchange During Overall Study Period = 93.5 percentage of participants (95% Confidence Interval, 82.5 - 97.8); -; -
Caplacizumab for pediatric immune thrombotic thrombocytopenic purpura: A scoping review of current evidence
Not Applicable; n=36; evaluation: Positive. Reported fields: AE = Minor bleeding occurred in 11%, with epistaxis, hematuria, and injection site reactions each in 6%. One case of jugular venous thrombosis was documented but not clearly attributed to treatment. In 36% of patients, no adverse events were reported. In 33% of cases, adverse events were not specified.
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Caplacizumab-YHDP addresses Purpura, Thrombotic Thrombocytopenic, Thrombotic Thrombocytopenic Purpura, Acquired. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Nanobody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2018-01-29 | Sanofi to acquire Ablynx for €3.9 Billion | Phase 2 | US$4,819.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
